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attenuated after adjusting for confounders (REM – 1.50, 1.38 and
1.27).
Conclusion: We confirmed poorer BCRS in older women in our
region. This was partially explained by known prognostic factors.
Further research is needed to determine whether biological differ-
ences or sub-optimal management can explain the residual
excess mortality.
doi:10.1016/j.ejcsup.2010.06.042
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Introduction: Biology of breast cancer appears to change with
age. Most studies are small/from multiple centres limiting their
importance.
Methods: From 1973 to 2009, 2000+ EPCs were managed in
Nottingham. Oestrogen receptor (ER) was assessed by immuno-
histochemistry (giving an H-score) on core biopsy for all
patients. A total of 831 patients had primary surgery and 575
had good quality tumour samples available for tissue micro-
array analysis.
Results: Comparing these 831 patients with a younger (<70
years) series (N = 1809), expression of ER (p < 0.001), p53, HER4,
CK14, bcl2 (p < 0.000) and CK 17 (p < 0.05) was found to increase
with age, while reverse was seen with CK 7/8 (p < 0.002), ki67
and E-Cadherin (p < 0.000). No change was observed in PR, HER2,
CK5/6, CK19 and MUC1 expression.
At 66-month median follow-up, for those who did not receive
adjuvant systemic therapy (N = 306), tumour size (p < 0.042), grade
(p < 0.046), axillary stage (p < 0.000) and PR (p < 0.017) were found
to be independent prognostic factors.
At 49-month median follow-up, for patients with ER+ (H-
scoreP 50) tumours, those with H-scoreP 250 had equivalent
5-year breast cancer specific survival (BCSS) regardless of primary
treatment (surgery vs primary endocrine therapy (PET) 95% ver-
sus 93%, p = 0.715). For patients on PET, all those with H-
scoreP 250 achieved clinical benefit as compared to 11 patients
with H-score < 250 who progressed, at 6 months (p < 0.03), the for-
mer also had better BCSS (p < 0.01).
Conclusion: The pattern suggests a less aggressive tumour phe-
notype with advancing age. The ER H-score appears as an excel-
lent surrogate for clinical outcome for ER+ EPCs. It is available
at diagnosis and has a great value in guiding discussion of thera-
peutic options.
doi:10.1016/j.ejcsup.2010.06.043
O-43 A KRAS MICRORNA BINDING SITE VARIANT IS A GENETIC
MARKER OF RISK FOR TRIPLE NEGATIVE BREAST CANCER
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versity of Ireland, Galway, Ireland. bDepartment of Molecular,
Cellular and Developmental Biology, Yale University, USA. cDepart-
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Introduction: MiRNAs exert their regulatory effect on gene
expression by binding to the 30 untranslated region (UTR) of target
mRNAs. The let-7 miRNA family are global genetic regulators crit-
ically important for controlling oncogene expression (e.g. KRAS).
Dysregulated let-7 expression is associated with many malignan-
cies including breast cancer, and it is hypothesized that defective
interaction between let-7 and its target KRAS underpins this asso-
ciation and oncogenesis. We hypothesized that a single nucleo-
tide polymorphism (SNP) in the let-7-binding site in KRAS
disrupts let-7 regulation of the oncogene and thus predisposes
to breast cancer.
Methods: A population analysis of the association of the KRAS
variant and breast cancer was performed on a cohort of 1010
breast cancer patients and 1497 age-matched healthy controls.
Genomic DNA isolated from all participants was amplified using
PCR assays designed specifically to identify the T (wild type) or
G (variant) allele. Genotyping results were correlated with
patients’ clinicopathological parameters.
Results: The KRAS variant was present in 15% of all breast can-
cer patients, compared with baseline prevalence of <7%. In partic-
ular the KRAS-variant predicted a significantly increased risk of
developing triple negative breast cancer in premenopausal
women (OR = 4.78, CI = 1.71–13.38, p = 0.015), and patients with
the variant allele were significantly more likely to present with
advanced stage disease (p = 0.03).
Conclusion: These seminal findings suggest that the KRAS-var-
iant acts as a genetic marker of risk for developing triple negative
breast cancer. Predicting risk for this subtype is critically impor-
tant, to permit early screening and intervention for ‘at-risk’
individuals.
doi:10.1016/j.ejcsup.2010.06.044
O-44 GENE–ENVIRONMENT INTERACTIONS IN 7610 WOMEN
WITH BREAST CANCER: PROSPECTIVE EVIDENCE FROM THE
MILLION WOMEN STUDY
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Tipper, Krys Baker, Valerie Beral, Richard Peto, John Bell, Diana
Zelenika, Mark Lathrop, for the Million Women Study
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Background: Genome-wide association studies, together with
analyses of specific candidate polymorphisms, have identified a
number of low-penetrance breast cancer susceptibility loci. Infor-
mation is scarce about the combined effects on breast cancer
incidence of these genetic variants and of environmental factors
(reproductive, behavioural, and anthropometric risk factors for
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breast cancer). To test for evidence of gene–environment interac-
tions, we compared genotypic relative risks for breast cancer
across categories of the environmental risk factors.
Methods: We tested gene–environment interactions in 7610
women who developed breast cancer and 10,196 controls without
the disease in a large UK prospective study, studying the effects of
12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-
rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451,
5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099,
TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively
collected information about 10 established environmental risk
factors (age at menarche, parity, age at first birth, breastfeeding,
menopausal status, age at menopause, use of hormone replace-
ment therapy, body-mass index, height, and alcohol consump-
tion).
Results: We will present findings from this systematic investi-
gation of gene–environment interactions in relation to breast can-
cer risk in the Million Women Study. Results from a meta-analysis
of these and published data will also be shown when possible.
doi:10.1016/j.ejcsup.2010.06.045
O-45 CHILDHOOD ADIPOSITY AND BREAST CANCER INCIDENCE
IN WOMEN IN MIDDLE AGE
Benjamin J. Cairns, TienYu Owen Yang, Gillian K. Reeves, Valerie
Beral, on behalf of the Million Women Study Collaborators. Cancer
Epidemiology Unit, University of Oxford, Oxford, UK
Among 397,339 postmenopausal women, breast cancer inci-
dence increases with increasing body mass index (BMI), while
adiposity in childhood has been found to lower risk. Few epidemi-
ological studies have been able to investigate joint effects of both
childhood and adult adiposity.
In a large, prospective study of postmenopausal middle-aged
women, adjusted relative risks (RR), according to BMI in middle
age and relative adiposity at age 10, were estimated by Cox regres-
sion. (Analyses were confined to non-users of hormone replace-
ment therapy, which can mask the effects of BMI on breast
cancer risk.)
Among 397,339 women, therewere 6189 incident breast cancers
over 5.2 years mean follow-up (average age at diagnosis: 63 years).
As expected, women with a high BMI in middle age had a greater
breast cancer risk (P < 0.001). In contrast, women who were plum-
per than average at age 10 had a lower risk of breast cancer than
women who were about average (P < 0.001). A similar apparently
protective effect of childhood adiposity was observed at each level
of women’s BMI in middle age (P = 0.08, NS, for interaction). These
relationships were not altered by height (P = 0.9), age at menarche
(P = 0.8), or other reproductive and hormonal risk factors (P > 0.1).
Despite the increase in risk of breast cancer with increasing
BMI among postmenopausal women, greater childhood adiposity
lowers risk in the same women. The reason for the persistent and
apparently protective effect of childhood adiposity is unclear.
doi:10.1016/j.ejcsup.2010.06.046
O-46 MACROPHAGE INFILTRATION IS ASSOCIATED WITH POOR
OUTCOME IN BREAST CANCER PATIENTS AND A REDUCED
TREATMENT RESPONSE TO LETROZOLE AND ZOLEDRONATE
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Background: Macrophage infiltration augments tumour recur-
rence whilst Zoledronic acid suppresses macrophage pro-
tumourigenicity. In the ZO-FAST and ABCSG 12 trials, oestrogen
receptor (ER) positive breast cancer patients received Zoledro-
nate in combination with an aromatase inhibitor, Letrozole,
demonstrating an increased disease-free survival. We aimed
to investigate macrophage infiltration and patient prognosis
and the early biological effects of adjunctive Zoledronate on
patient and macrophage response to treatment in breast
cancer.
Methods: Tissue microarrays from 179 breast cancer ‘FasA
Cohort’ patients were immunohistochemically stained with
CD68, a universal macrophage marker. A randomised pre-opera-
tive trial allocated ER-positive breast cancer patients (n = 110) to
14 days pre-operative treatment of Letrozole, Letrozole and
Zoledronate, or placebo. Pre- and post-treatment specimens were
collected and immunohistochemically stained for CD68 and the
proliferation marker, Ki67.
Results: The FasA cohort found links between macrophage fre-
quency and tumour grade (P < 0.01), size (P < 0.05), recurrence
(P < 0.05) and lymph node status (P < 0.05). Ki67 reductions of 52%
(P < 0.001) were seen in the aromatase inhibitor group, with no
additional benefit following Zoledronate treatment. Macrophage
infiltrate (Mean = 37; Range = 3–117) was positively associated with
pre and post Ki67 levels (P < 0.05, P < 0.01). Additionally, low post-
treatment macrophage infiltrate (Mean = 29; Range = 3–66) was
associated with a greater reduction in Ki67 following aromatase
inhibition (P < 0.05).
Conclusion: Macrophage infiltrate correlates with poor outcome
in breast cancer. Aromatase inhibition but not Zoledronate low-
ered proliferation and macrophage infiltration in ER-positive
breast cancer. For the first time we have shown novel treatment
effects on the tumour stromal compartment.
doi:10.1016/j.ejcsup.2010.06.047
O-47 THE BASO II TRIAL AT MEDIAN 15 YEARS OF FOLLOW-UP
R.W. Blamey, A. Oates, data manager, on behalf of the
Contributors to BASO II. Nottingham City Hospital, UK
BASO II tested whether adjuvant radiotherapy or endocrine
therapy were required following Wide Local Excision: Grade I/
node negative/62 cm diameter.
The mean endpoint was Local Recurrence (in breast) (LR).
Entry was to 4-way randomisation: RT only, Tamoxifen (TAM)
only, neither, both.
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